Recombinant Human LILRB4/CD85k/ILT3 Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

ILT3, also known as CD85k and LIR-5, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation (1). Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2). Alternative splicing of human ILT3 generates an isoform that lacks the first ITIM and a secreted isoform that circulates in the serum of cancer patients (3, 4). ILT3 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC) (2, 5, 6). Ligation of ILT3 triggers ITIM-mediated inhibition of cell-activating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection (2, 4, 7, 8). Soluble ILT3 induces the differentiation of CD8⁺ T suppressor cells (Ts) that can inhibit the effector functions of CD4⁺ Th cells and CD8⁺ CTL (4, 7, 9). In turn, CD8⁺ Ts cells induce ILT3 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC (5, 6, 8, 10, 11).

Array 8488-T4

• ILT3/CD85k/LILRB4 Antibodies
• ILT3/CD85k/LILRB4 ELISA Kits
• ILT3/CD85k/LILRB4 Lysates
• ILT3/CD85k/LILRB4 Proteins and Enzymes